Cargando…

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly

OBJECTIVE: To evaluate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of acromegaly. DESIGN AND PATIENTS: Ninety-eight previously untreated acromegalics were recruited into this prospective multicentre study. A total of 68 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Mercado, Moises, Borges, Fatima, Bouterfa, Hakim, Chang, Tien-Chun, Chervin, Alberto, Farrall, Andrew J, Patocs, Attila, Petersenn, Stephan, Podoba, Jan, Safari, Mitra, Wardlaw, Joanna
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1974838/
https://www.ncbi.nlm.nih.gov/pubmed/17465997
http://dx.doi.org/10.1111/j.1365-2265.2007.02825.x
_version_ 1782135051418337280
author Mercado, Moises
Borges, Fatima
Bouterfa, Hakim
Chang, Tien-Chun
Chervin, Alberto
Farrall, Andrew J
Patocs, Attila
Petersenn, Stephan
Podoba, Jan
Safari, Mitra
Wardlaw, Joanna
author_facet Mercado, Moises
Borges, Fatima
Bouterfa, Hakim
Chang, Tien-Chun
Chervin, Alberto
Farrall, Andrew J
Patocs, Attila
Petersenn, Stephan
Podoba, Jan
Safari, Mitra
Wardlaw, Joanna
author_sort Mercado, Moises
collection PubMed
description OBJECTIVE: To evaluate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of acromegaly. DESIGN AND PATIENTS: Ninety-eight previously untreated acromegalics were recruited into this prospective multicentre study. A total of 68 patients successfully completed 48 weeks of the study period, received 12 doses of octreotide LAR 10–30 mg every 4 weeks, and constituted the population used for this analysis. MEASUREMENTS AND RESULTS: A clinically relevant reduction (i.e. to ≤ 5 µg/l) in mean GH (mGH) was recorded in 72% of patients after 24 weeks of treatment, and 42% reached a ‘safe’ GH value (≤ 2·5 µg/l). At week 48, 16 more patients were considered partial GH responders (GH > 2·5 µg/l and ≤ 5 µg/l) and 44% had reached a GH level ≤ 2·5 µg/l. IGF-1 levels normalized in 38% and 34% of patients after 24 and 48 weeks of treatment, respectively. At study completion, 10 patients (14·7%) who had not normalized their IGF-1 levels had achieved at least a 50% decrement in this marker. In eight microadenoma patients, tumour volume decreased from a mean baseline level of 298 ± 145 mm(3) to 139 ± 94 mm(3) after 24 weeks and to 99 ± 70 mm(3) after 48 weeks of therapy. In 60 patients with macroadenoma, the corresponding values were 3885 ± 5077 mm(3) at baseline and 2723 ± 3435 and 2406 ± 3207 mm(3) after 24 and 48 weeks, respectively. At weeks 24 and 48, a significant (> 20%) tumour volume reduction was reported in 63% and 75% of patients, respectively. A reduction in the severity of symptoms of acromegaly was observed early in treatment and was maintained throughout the study period. CONCLUSION: Octreotide LAR represents a viable alternative to surgery for primary treatment of acromegaly leading to a progressive regression of tumour volume, a sustained control of biochemical abnormalities and an adequate relief of symptoms of the disease.
format Text
id pubmed-1974838
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-19748382007-09-10 A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly Mercado, Moises Borges, Fatima Bouterfa, Hakim Chang, Tien-Chun Chervin, Alberto Farrall, Andrew J Patocs, Attila Petersenn, Stephan Podoba, Jan Safari, Mitra Wardlaw, Joanna Clin Endocrinol (Oxf) Original Articles OBJECTIVE: To evaluate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of acromegaly. DESIGN AND PATIENTS: Ninety-eight previously untreated acromegalics were recruited into this prospective multicentre study. A total of 68 patients successfully completed 48 weeks of the study period, received 12 doses of octreotide LAR 10–30 mg every 4 weeks, and constituted the population used for this analysis. MEASUREMENTS AND RESULTS: A clinically relevant reduction (i.e. to ≤ 5 µg/l) in mean GH (mGH) was recorded in 72% of patients after 24 weeks of treatment, and 42% reached a ‘safe’ GH value (≤ 2·5 µg/l). At week 48, 16 more patients were considered partial GH responders (GH > 2·5 µg/l and ≤ 5 µg/l) and 44% had reached a GH level ≤ 2·5 µg/l. IGF-1 levels normalized in 38% and 34% of patients after 24 and 48 weeks of treatment, respectively. At study completion, 10 patients (14·7%) who had not normalized their IGF-1 levels had achieved at least a 50% decrement in this marker. In eight microadenoma patients, tumour volume decreased from a mean baseline level of 298 ± 145 mm(3) to 139 ± 94 mm(3) after 24 weeks and to 99 ± 70 mm(3) after 48 weeks of therapy. In 60 patients with macroadenoma, the corresponding values were 3885 ± 5077 mm(3) at baseline and 2723 ± 3435 and 2406 ± 3207 mm(3) after 24 and 48 weeks, respectively. At weeks 24 and 48, a significant (> 20%) tumour volume reduction was reported in 63% and 75% of patients, respectively. A reduction in the severity of symptoms of acromegaly was observed early in treatment and was maintained throughout the study period. CONCLUSION: Octreotide LAR represents a viable alternative to surgery for primary treatment of acromegaly leading to a progressive regression of tumour volume, a sustained control of biochemical abnormalities and an adequate relief of symptoms of the disease. Blackwell Publishing Ltd 2007-06-01 /pmc/articles/PMC1974838/ /pubmed/17465997 http://dx.doi.org/10.1111/j.1365-2265.2007.02825.x Text en © 2007 The Authors Journal compilation © 2007 Blackwell Publishing Ltd https://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2·5, which does not permit commercial exploitation.
spellingShingle Original Articles
Mercado, Moises
Borges, Fatima
Bouterfa, Hakim
Chang, Tien-Chun
Chervin, Alberto
Farrall, Andrew J
Patocs, Attila
Petersenn, Stephan
Podoba, Jan
Safari, Mitra
Wardlaw, Joanna
A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
title A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
title_full A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
title_fullStr A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
title_full_unstemmed A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
title_short A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
title_sort prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide lar® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1974838/
https://www.ncbi.nlm.nih.gov/pubmed/17465997
http://dx.doi.org/10.1111/j.1365-2265.2007.02825.x
work_keys_str_mv AT mercadomoises aprospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly
AT borgesfatima aprospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly
AT bouterfahakim aprospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly
AT changtienchun aprospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly
AT chervinalberto aprospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly
AT farrallandrewj aprospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly
AT patocsattila aprospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly
AT petersennstephan aprospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly
AT podobajan aprospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly
AT safarimitra aprospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly
AT wardlawjoanna aprospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly
AT mercadomoises prospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly
AT borgesfatima prospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly
AT bouterfahakim prospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly
AT changtienchun prospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly
AT chervinalberto prospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly
AT farrallandrewj prospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly
AT patocsattila prospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly
AT petersennstephan prospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly
AT podobajan prospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly
AT safarimitra prospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly
AT wardlawjoanna prospectivemulticentrestudytoinvestigatetheefficacysafetyandtolerabilityofoctreotidelarlongactingrepeatableoctreotideintheprimarytherapyofpatientswithacromegaly